While clinical trials of Src inhibitors failed to show efficacy in patients with advanced metastatic disease [29, 44], present data may offer some explanation for this failure in indicating that Src and p300 participate in the migratory and invasive properties of PDAC cells rather than survival signaling. This evidence concerns the gene SRC and metastatic neoplasm.